Nuformix plc (NFX.L) Research

Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.

Market snapshot

Symbol
NFX.L
Price
$0.19
Day change
+9.79%
Market cap
$3.9M
P/E ratio
-3.93x
52-week range
0.071-0.555
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • Cizzle Biotechnology Holdings Plc (CIZ.L)
  • Futura Medical plc (FUM.L)
  • Genflow Biosciences plc (GENF.L)
  • GENinCode plc (GENI.L)
  • IXICO plc (IXI.L)
  • Oxford BioDynamics Plc (OBD.L)
  • OptiBiotix Health Plc (OPTI.L)
  • Theracryf Plc (TCF.L)

Open Nuformix plc (NFX.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.